Innovative drug infusion technology for laboratory animals.

Japanese English
resources e-book video slide qa
SMP-310R SMP-200 null null null null null null null null


  • NewsDiscovery and Characterization of JDQ443: a Structurally Novel Covalent Inhibitor of KRASG12C

    Elizabeth McKenna, PhD, interviews Saskia Brachmann, PhD, Anna Farago, MD, PhD, and Andreas Weiss, PhD, about their paper describing a novel KRAS G12C inhibitor that was published concurrently with a Clinical Trials Minisymposium presentation at the 2022 AACR Annual Meeting. iPRECIO SMP-310R Programmable pumps were used to better understand the relationship between PK, target occupancy, and efficacy.

    July 7, 2022

  • Event[Webinar] "Discovery of JDQ443, a structurally novel, potent and selective covalent oral inhibitor of KRASG12C"; MedChemCASES #16: Dr. Simona Cotesta - " We describe the hit to lead and lead optimization by structure-based design of the novel chemical series leading to the discovery of NVP-JDQ443 (JDQ443), a novel, potent and selective, orally bioavailable KRASG12C covalent inhibitor. JDQ443 showed dose dependent antitumor efficacy in KRAS G12C-mutated cell-derived models and is currently in clinical development as monotherapy as well as in combination with TNO155, a SHP2 inhibitor (NCT04699188). " excerpt from

    dr Simona Cotesta (Novartis)
    June 22, 2022
    5:00 PM (Berlin time)
    Registration link:

    June 17, 2022

  • NewsiPRECIO SMP-310R Programmable pumps were used to better understand the relationship between PK, target occupancy, and efficacy.
    " These findings demonstrate that antitumor activity can be achieved under both q.d. and b.i.d. dosing. To better understand the relationship between PK, target occupancy, and efficacy, a continuous infusion xenograft study was performed in the LU99 xenograft model and the PK/TO model applied to estimate the resulting levels of KRAS(G12C) target occupancy. " excerpt from publication, "Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRAS(G12C) Wiess et al. Cancer Discov OF1–OF18. [Open Access]

    June 1, 2022

  • EventNow all open access. No registration required: Compound Delivery, PK-PD, & Validation Studies in Oncology Research.
    Slide deck, Expert Answers, Q&A Report, and On-demand Webinar< here >. Learn how Christian Schnell, Associate Director Oncology NIBR, Novartis Pharma AG, Basel, CH reached his conclusions.

    January 5, 2022

  • NewsOur iPRECIO Mouse pumps were mentioned by Jamie Oliver Chief Medical Officer of Starton Therapeutics at Precision Blood Cancer Symposium September 2021. Presentation available <here>

    November 15, 2021


Our Mission with
iPRECIO® Product Portfolio:

Make it as easy as possible to evaluate efficacy of molecules/agents in different animal models and species.

Make the results as relevant as possible to the clinic. (Exposure profile, quantitative pharmacology, untethered free moving (stress free, group housing (socialization), ..…)

The use of iPRECIO® pumps will have a positive impact on experimental conditions and the relevance of results achieved. Initial costs maybe higher but in the long run the use of the pump could be cost saving in the context of the whole compound development.

insidescientific e-book insidescientific slide qanda

Page top

Privacy Policy